NEW YORK, June 21 - Accelrys announced it will acquire Synomics in a stock transaction valued at $4 million, the companies announced Thursday.
Accelrys, based in San Diego and Cambridge, UK, and a subsidiary of Pharmacopeia of Princeton, NJ, agreed to acquire all outstanding stock of privately-held Synomics. The companies believe the transaction will be completed within several days.
"The acquisition of Synomics marks another significant step towards the development by Accelrys of a comprehensive, integrated software platform for research and development," Michael Stapleton, chief operating officer of Accelrys, said in a statement. "In addition to strengthening our strategic technology position, the acquisition will provide us with 40 highly qualified staff who will be quickly integrated, primarily into our new consulting organization."
Stapleton added that the acquisition may "slightly dilute" Accelry's earnings for the remainder of 2001 as the company integrates Synomics software into its own technology and its sales and marketing network.
Synomics, a developer of enterprise-wide software systems, is based in Cambridge, UK.
Accelrys was formed in April when Pharmacopeia merged its software subsidiaries.